According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

and lens rotation. The fixed variables were the sample of eyes with preoperative keratometry data, the presumed surgically induced astigmatism for use in the Acrysof ® Toric ® IOL calculator and ...

Cataract surgery is a life-changing procedure that can restore clear vision and improve the quality of life. One needs to be ...

A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global Intraocular Lens (IOL) market ...

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...

Cataracts, a common eye condition that clouds vision and hampers daily activities, can now be treated with innovative ...

The intraocular lens (IOL ... Advancements in technology, like multifocal and toric lenses, enhance visual results further boosting the market demand. The rise in minimally invasive cataract ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...